A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Latest Information Update: 14 Jun 2025
At a glance
- Drugs Povorcitinib (Primary)
- Indications Asthma; Chronic urticaria; Hidradenitis suppurativa; Prurigo nodularis; Vitiligo
- Focus Adverse reactions; Registrational
- Acronyms STOP-LTR
- Sponsors Incyte Corporation
Most Recent Events
- 24 Mar 2025 Status changed from not yet recruiting to recruiting.
- 06 Mar 2025 New trial record